AbbVie Inc.

ABBV · Mega cap · 3 articles

Financial highlights

Metric	FY 12/31/25	FY 12/31/24	FY 12/31/23	FY 12/31/22	FY 12/31/21
Income Statement
Revenue	$61.2B	$56.3B	$54.3B	$58.1B	$56.2B
Cost of revenue	$18.2B	$16.9B	$20.4B	$17.4B	$17.4B
Selling, general & administrative	$14.0B	$14.8B	$12.9B	$15.3B	$12.3B
Research and development	$9.1B	$12.8B	$7.7B	$6.5B	$6.9B
Operating income	$15.1B	$9.1B	$12.8B	$18.1B	$17.9B
Interest expense	$2.9B	$2.8B	$2.2B	$2.2B	$2.4B
Pretax income	$6.6B	$3.7B	$6.2B	$13.5B	$13.0B
Income tax expense	$2.4B	-$570.0M	$1.4B	$1.6B	$1.4B
Net income	$4.2B	$4.3B	$4.9B	$11.8B	$11.5B
Balance Sheet
Cash and equivalents	$5.2B	$5.5B	$12.8B	$9.2B	$9.7B
Current assets	$29.1B	$25.6B	$33.0B	$28.5B	$27.9B
Total assets	$134.0B	$135.2B	$134.7B	$138.8B	$146.5B
Current liabilities	$43.3B	$38.7B	$37.8B	$29.5B	$35.2B
Total debt	$65.0B	$67.1B	$59.4B	$63.3B	$76.7B
Stockholders' equity	-$3.3B	$3.3B	$10.4B	$17.3B	$15.4B
Cash Flow Statement
Cash from operations	$19.0B	$18.8B	$22.8B	$24.9B	$22.8B
Depreciation and amortization	$762.0M	$764.0M	$752.0M	$778.0M	$803.0M
Stock-based compensation	$955.0M	$911.0M	$747.0M	$671.0M	$692.0M
Capital expenditure	$1.2B	$974.0M	$777.0M	$695.0M	$787.0M
Free cash flow	$17.8B	$17.8B	$22.1B	$24.2B	$22.0B
Dividends paid	$11.7B	$11.0B	$10.5B	$10.0B	$9.3B
Share repurchases	$980.0M	$1.7B	$2.0B	$1.5B	$934.0M

Shares outstanding 1.8B · Free float 99.9%

Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.